The structural basis for the increased immunogenicity of two HIV-reverse transcriptase peptide variant/class I major histocompatibility complexes.
Kirksey, T.J., Pogue-Caley, R.R., Frelinger, J.A., Collins, E.J.(1999) J Biol Chem 274: 37259-37264
- PubMed: 10601290 
- DOI: 10.1074/jbc.274.52.37259
- Primary Citation of Related Structures:  
1I1F, 1I1Y - PubMed Abstract: 
Designing altered peptide ligands to generate specific immunological reactivity when bound to class I major histocompatibility complexes is important for both therapeutic and prophylactic reasons. We have previously shown that two altered peptides, derived from human immunodeficiency virus (HIV)-reverse transcriptase (RT) residues 309-317, are more immunogenic in vitro than the wild-type peptide ...